NCT06523387 Online Pivotal Response Treatment Training in Autism Spectrum Disorder
| NCT ID | NCT06523387 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Autism Spectrum Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 44 participants |
| Start Date | 2026-01-30 |
| Primary Completion | 2028-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 44 participants in total. It began in 2026-01-30 with a primary completion date of 2028-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a research study that will assess the effects of a Pivotal Response Treatment Online Training Course (PRT-O) for training parents of children with Autism Spectrum Disorder (ASD). The study will specifically investigate whether participants can learn to deliver PRT effectively following participation in the Online training.
Eligibility Criteria
Inclusion Criteria: * 2:0 to 5:11 years at the time of consent, * diagnosed with ASD (based on history, review of available medical records including diagnostic testing, e.g., Autism Diagnostic Observation Schedule) or suspicion of Autism Spectrum Disorder diagnosis, and confirmed with Autism Diagnostic Interview-Revised (ADI-R), * with significant adaptive communication deficits (i.e., either a Vineland-3 Communication subscale 2 Standard Deviations below average for 2 and 3 year olds and 3 Standard Deviations below for 4 and 5 year olds or a Vineland-3 Expressive V-scale Score 2 Standard Deviations below average for 2 and 3 year olds, or 3 Standard Deviations below for 4 and 5 year old, and at least moderate severity on the Clinical Global Impressions Severity (CGI-S) language subscale), * an English-speaking parent able to consistently participate in study procedures and conduct treatment in English, * stable psychotropic medication(s) or biomedical intervention(s) for at least 1 month prior to baseline measurements with no anticipated changes during study participation, * stable treatment (ABA, Floortime, or other interventions), speech therapy, and school placement for at least 1 month prior to baseline measurements with no expected changes during study participation, * no more than 60 minutes of 1:1 speech therapy per week Exclusion Criteria: * Children who have a primary language other than English * parent or child diagnosed with severe psychiatric disorder or unstable medical problem * previous adequate trial of pivotal response treatment resulting in parent meeting Pivotal Response Treatment fidelity of implementation at baseline * Receiving more than 15 hours of in home 1:1 ABA per week * living within 100 miles of Stanford University.
Contact & Investigator
Grace Gengoux, PhD
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT06523387 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 5 Years, studying Autism Spectrum Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06523387 currently recruiting?
Yes, NCT06523387 is actively recruiting participants. Contact the research team at autismdd@stanford.edu for enrollment information.
Where is the NCT06523387 trial being conducted?
This trial is being conducted at Stanford, United States.
Who is sponsoring the NCT06523387 clinical trial?
NCT06523387 is sponsored by Stanford University. The principal investigator is Grace Gengoux, PhD at Stanford University. The trial plans to enroll 44 participants.